Heilongjiang ZBD Pharmaceutical Co., Ltd.
Market Snapshot
- Stock Symbol: SH603567
- Exchange: Shanghai Stock Exchange (China)
- Currency: CNY
- Latest Closing Price (2026‑07‑21): 5.91 CNY
- 52‑Week High: 13.48 CNY (2025‑08‑05)
- 52‑Week Low: 4.21 CNY (2026‑06‑28)
- Market Capitalisation: 5,556,790,272 CNY
- Price‑to‑Earnings Ratio: –3.4 (negative earnings)
Company Profile
Heilongjiang ZBD Pharmaceutical Co., Ltd. is a health‑care enterprise headquartered in Hulin, China. The company focuses on the research, manufacturing, and distribution of a broad spectrum of pharmaceutical products, including cardiovascular drugs, antibacterials, orthopedic agents, detoxification agents, and pediatric medicines. Its products are marketed throughout the country, supplying a range of hospitals, pharmacies, and healthcare providers.
Current Financial Standing
| Item | Value |
|---|---|
| Revenue | Not disclosed in the available data |
| Net Profit | Negative (exact figures not provided) |
| P/E Ratio | –3.4, indicating the company is currently reporting a loss |
| Operating Segments | Cardiovascular, antibacterial, orthopedic, detoxification, pediatric |
Market Context
- Sector Performance: The health‑care and pharmaceutical sector in China has experienced mixed results, with regulatory changes and pricing pressures affecting profitability for many manufacturers.
- Competitive Landscape: Heilongjiang ZBD competes with domestic producers that offer similar therapeutic categories, as well as with international firms that have a presence in China’s pharmaceutical market.
- Regulatory Environment: The Chinese government continues to tighten drug pricing and reimbursement policies, which can influence sales volumes and margins for companies like Heilongjiang ZBD.
Strategic Considerations
Product Portfolio Diversification Expanding into high‑margin therapeutic areas could help offset current losses. The company’s existing focus on cardiovascular and pediatric drugs positions it well for potential growth in these segments.
Supply Chain Optimization Enhancing manufacturing efficiencies and reducing production costs will be critical to improving profitability in a highly competitive market.
Regulatory Compliance Maintaining robust quality control and compliance with China’s drug approval processes is essential to sustain market access and avoid costly setbacks.
Investment Outlook Given the negative earnings and low price‑to‑earnings ratio, the stock may appeal to investors seeking high‑risk, high‑reward opportunities. However, the lack of disclosed revenue figures and ongoing losses suggest caution.
Conclusion
Heilongjiang ZBD Pharmaceutical Co., Ltd. remains a significant player in China’s pharmaceutical landscape, offering a diverse array of products across several therapeutic categories. While the company is currently operating at a loss, strategic initiatives focused on product diversification, cost control, and regulatory compliance could position it for improved financial performance in the coming years. Investors should weigh the company’s potential for growth against the risks inherent in a highly regulated and competitive industry.
